Pages : 231 | Published Date : 2026-05-18 | Report Code : IR1272

The Global Antibody-Drug Conjugate Market was valued at approximately USD 7.60 Billion in 2024 and reached USD 8.94 Billion in 2025. The market is projected to grow to USD 38.76 Billion by 2034, expanding at a CAGR of 17.7% during the forecast period from 2026 to 2034. This strong valuation is driven by the "2026 Precision Oncology Pivot," as major healthcare networks change cancer treatment protocols to use targeted biologics that reduce overall toxicity. Moreover, the 2026 advancement of automated bioconjugation systems has greatly reduced batch-to-batch variability. This improvement allows Contract Development and Manufacturing Organizations (CDMOs) to meet the strict purity standards set by global regulators and speeds up the commercial release of late-stage pipelines.

Pages : 231 | Published Date : 2026-05-18 | Report Code : IR1271

The Global Smart Pill Technology Market was valued at approximately USD 2.33 Billion in 2024 and reached USD 2.64 Billion in 2025. The market is projected to grow to USD 8.21 Billion by 2034, expanding at a CAGR of 13.4% during the forecast period from 2026 to 2034. This valuation is driven by the "2026 Non-Invasive Diagnostic Shift." Healthcare networks are rapidly adopting ingestible capsules to address falling compliance rates for traditional optical colonoscopies. Additionally, the 2026 introduction of "Real-Time AI Video Triage Tools" reduces physician video-review times from an hour to under fifteen minutes. This has significantly cut the administrative cost per procedure, turning smart pills from a niche secondary diagnostic tool into a common, efficient frontline screening solution.

Pages : 215 | Published Date : 2026-05-16 | Report Code : IR1270

The Global AI in Radiology Market was valued at approximately USD 1.68 Billion in 2024 and reached USD 2.14 Billion in 2025. The market is projected to grow to USD 18.73 Billion by 2034, expanding at a CAGR of 27.2% during the forecast period from 2026 to 2034. This soaring valuation is driven by the "2026 Emergency Triage Inflection," where high-volume acute care settings have made AI-driven prioritization a standard operational mandate. Furthermore, the 2026 integration of "PACS-Native Diagnostic Assistants"—which embed deep learning directly into existing viewer interfaces—has drastically accelerated clinical workflows, successfully cutting regular study interpretation times by a quarter and delivering immediate operational ROI to overburdened health networks.

Pages : 232 | Published Date : 2026-05-16 | Report Code : IR1269

The Global Large Vision Model Market was valued at approximately USD 6.51 Billion in 2024 and reached USD 7.84 Billion in 2025. The market is projected to grow to USD 41.56 Billion by 2034, expanding at a CAGR of 20.4% during the forecast period from 2026 to 2034. This exponential valuation is driven by the "2026 Shift to Cross-Modal Production Systems," as enterprises phase out single-task computer vision pipelines in favor of generalizable foundation models that seamlessly bridge visual inputs with contextual language data. Furthermore, the 2026 standardization of sub-80 millisecond inference on specialized edge accelerators has unlocked real-time automated inspection for high-throughput manufacturing lines, establishing LVMs as a foundational pillar of modern industrial automation.

Pages : 241 | Published Date : 2026-05-16 | Report Code : IR1268

Neural Processing Unit Market

Pages : 245 | Published Date : 2026-05-15 | Report Code : IR1267

The Global Advanced Photomask Material Market was valued at approximately USD 4.78 Billion in 2024 and reached USD 5.18 Billion in 2025. The market is projected to grow to USD 10.74 Billion by 2034, expanding at a CAGR of 8.4% during the forecast period from 2026 to 2034. This valuation is driven by the "2026 High-NA Transition," as the industry moves toward pilot-line production for the 2nm node, requiring entirely new absorber materials and ultra-flat blanks. Furthermore, the 2026 commercialization of "High-Transmittance Carbon Nanotube (CNT) Pellicles"—capable of withstanding 600W+ EUV source power—is effectively eliminating the thermal degradation bottleneck, allowing logic foundries to maximize scanner throughput and justifying the premium pricing of next-generation mask stacks.

Pages : 234 | Published Date : 2026-05-15 | Report Code : IR1266

The Global Bioprocess Analytics Market was valued at approximately USD 3.92 Billion in 2024 and reached USD 4.26 Billion in 2025. The market is projected to grow to USD 8.97 Billion by 2034, expanding at a CAGR of 8.6% during the forecast period from 2026 to 2034. This valuation is driven by the "2026 Digital Bio-Manufacturing Pivot," as the industry moves away from retrospective testing toward real-time monitoring of complex viral vectors and cell therapies. Furthermore, the 2026 maturation of "Self-Correcting Bioreactor" systems—which use integrated analytics to automatically adjust pH and dissolved oxygen levels—is reducing batch failure rates by up to 40%, providing a decisive ROI for manufacturers operating in the high-stakes biologics sector.

Pages : 240 | Published Date : 2026-05-15 | Report Code : IR1265

The Global Aerospace Composites Market was valued at approximately USD 32.80 Billion in 2024 and reached USD 34.80 Billion in 2025. The market is projected to grow to USD 59.20 Billion by 2034, expanding at a CAGR of 6.1% during the forecast period from 2026 to 2034. This robust valuation is driven by the "2026 Fleet Modernization Peak," as Boeing and Airbus accelerate deliveries to clear historic backlogs while meeting stringent new global carbon-offset mandates. Furthermore, the 2026 maturation of "High-Rate Thermoplastic Stamping"—which has reduced cycle times for secondary structural parts from hours to minutes—is effectively lowering the cost-per-part, allowing composites to displace aluminum in high-volume single-aisle aircraft programs.

Pages : 241 | Published Date : 2026-05-14 | Report Code : IR1264

The Global Flow Cytometry Market was valued at approximately USD 6.56 Billion in 2024 and reached USD 7.28 Billion in 2025. The market is projected to grow to USD 18.64 Billion by 2034, expanding at a CAGR of 11.0% during the forecast period from 2026 to 2034. This robust growth is anchored by the "2026 Cell Therapy Industrialization," as manufacturing of CAR-T and TCR therapies shifts toward automated, GMP-compliant systems that require continuous flow cytometric monitoring. Furthermore, the 2026 maturation of "Spectral Multi-Omics"—which combines high-parameter protein detection with transcriptomic tagging—is effectively doubling the data output per cell, allowing researchers to map the entire human immune system with a resolution that was computationally impossible just three years ago.

Pages : 215 | Published Date : 2026-05-14 | Report Code : IR1263

The Global Automotive Lightweight Composite Market was valued at approximately USD 11.62 Billion in 2024 and reached USD 12.84 Billion in 2025. The market is projected to grow to USD 31.62 Billion by 2034, expanding at a CAGR of 10.5% during the forecast period from 2026 to 2034. This robust valuation is driven by the "2026 Fleet Compliance Peak," as European and Chinese OEMs aggressively adopt Carbon Fiber Reinforced Polymers (CFRP) to meet tightening emission mandates. Furthermore, the 2026 breakthrough in "High-Speed Thermoplastic Pressing"—which has reduced cycle times for structural composite parts to under 60 seconds—is effectively bridging the productivity gap with traditional steel stamping, allowing composites to move from luxury performance vehicles into high-volume mass-market platforms.

Pages : 241 | Published Date : 2026-05-14 | Report Code : IR1262

The Global API Security Platform Market was valued at approximately USD 6.03 Billion in 2024 and reached USD 6.84 Billion in 2025. The market is projected to grow to USD 21.47 Billion by 2034, expanding at a CAGR of 13.5% during the forecast period from 2026 to 2034. This robust growth is anchored by the "2026 API Visibility Mandate," as the proliferation of shadow APIs and microservices has made automated discovery a core requirement for cyber insurance eligibility. Furthermore, the 2026 maturation of "Business Logic Attack Prevention"—which uses AI to identify sophisticated API abuse that mimics legitimate user behavior—is effectively reducing fraud losses by nearly 50%, providing an immediate and quantifiable ROI for enterprise security investments.

Pages : 231 | Published Date : 2026-05-14 | Report Code : IR1261

The Global Compliance Workflow Automation Market was valued at approximately USD 6.57 Billion in 2024 and reached USD 7.42 Billion in 2025. The market is projected to grow to USD 22.18 Billion by 2034, expanding at a CAGR of 12.9% during the forecast period from 2026 to 2034. This robust valuation is anchored by the "2026 Regulatory Convergence," where the simultaneous activation of the EU AI Act and expanded SEC climate disclosures has made manual tracking impossible for multinational firms. Furthermore, the 2026 maturation of "Autonomous Control Testing"—AI agents that continuously audit financial and data systems without human intervention—is reducing the cost of audit readiness by nearly 65%, allowing mid-market firms to achieve Tier-1 levels of compliance at a fraction of the historical cost.

Pages : 241 | Published Date : 2026-05-11 | Report Code : IR1260

The Global Shape Memory Polymer Market was valued at approximately USD 1.91 Billion in 2024 and reached USD 2.14 Billion in 2025. The market is projected to grow to USD 5.87 Billion by 2034, expanding at a CAGR of 11.9% during the forecast period from 2026 to 2034. This valuation is driven by the "2026 Clinical Adoption Surge," as SMP-based stents and neurovascular coils have moved from niche applications to standard-of-care in major health systems. Furthermore, the 2026 commercialization of "High-Precision 4D Resins" has enabled the aerospace sector to replace complex hydraulic actuators with lightweight, self-deploying SMP structures, reducing satellite launch weights by up to 15% and significantly lowering mission costs.

Pages : 225 | Published Date : 2026-05-11 | Report Code : IR1259

The Global Medical Affairs Technology Market was valued at approximately USD 4.82 Billion in 2024 and reached USD 5.38 Billion in 2025. The market is projected to grow to USD 14.92 Billion by 2034, expanding at a CAGR of 11.7% during the forecast period from 2026 to 2034. This valuation is underpinned by the "2026 Scientific Exchange Pivot," as the industry moves away from static CRM systems toward specialized platforms that can handle the nuanced requirements of precision medicine launches. Furthermore, the 2026 maturation of "Compliance-by-Design" AI frameworks—which provide real-time monitoring of Medical Science Liaison (MSL) interactions—is effectively reducing regulatory risk, allowing companies to navigate complex global enforcement environments with significantly higher clinical and legal confidence.

Pages : 231 | Published Date : 2026-05-11 | Report Code : IR1258

The Global Regulatory Information Management Market was valued at approximately USD 2.17 Billion in 2024 and reached USD 2.38 Billion in 2025. The market is projected to grow to USD 5.47 Billion by 2034, expanding at a CAGR of 9.7% during the forecast period from 2026 to 2034. This growth is anchored by the "2026 Global eCTD v4.0 Migration," as health authorities worldwide shift toward more granular, metadata-driven submission standards. Furthermore, the 2026 introduction of "Predictive Regulatory Intelligence"—which uses AI to cross-reference global submission changes with internal product portfolios in real-time—is effectively reducing the risk of non-compliance for multinational firms, allowing them to manage complex, parallel filings across dozens of jurisdictions with a 40% reduction in manual oversight.

Pages : 241 | Published Date : 2026-05-09 | Report Code : IR1257

The Global Pharmacovigilance Software Market was valued at approximately USD 1.62 Billion in 2024 and reached USD 1.82 Billion in 2025. The market is projected to grow to USD 5.11 Billion by 2034, expanding at a CAGR of 12.2% during the forecast period from 2026 to 2034. This robust growth is anchored by the "2026 Global Standard Harmonization," as over 60 nations have now mandated ICH E2B(R3) compliance, making legacy manual systems obsolete. Furthermore, the 2026 introduction of "Predictive Signal Detection"—which allows AI to identify safety risks in real-world data months before they appear in spontaneous reports—is effectively moving the industry from a reactive compliance model to a proactive patient safety paradigm, significantly reducing potential litigation and recall costs.

Pages : 230 | Published Date : 2026-05-09 | Report Code : IR1256

The Global Patient Recruitment Platform Market was valued at approximately USD 1.65 Billion in 2024 and reached USD 1.85 Billion in 2025. The market is projected to grow to USD 5.10 Billion by 2034, expanding at a CAGR of 12.0% during the forecast period from 2026 to 2034. This growth is anchored by the "2026 Diversity Enforcement Wave," as the FDA’s full implementation of mandatory Diversity Action Plans has made recruitment technology a non-discretionary compliance expense. Furthermore, the 2026 maturation of "Hyper-Local Recruitment Architectures"—which integrate telemedicine and mobile nursing into recruitment funnels—is effectively doubling the addressable patient pool by removing the "geographic tax" that previously excluded 70% of potential participants living more than 50 miles from traditional research sites.

Pages : 221 | Published Date : 2026-05-09 | Report Code : IR1255

The Global Electronic Data Capture System Market was valued at approximately USD 7.63 Billion in 2024 and reached USD 8.20 Billion in 2025. The market is projected to grow to USD 15.70 Billion by 2034, expanding at a CAGR of 7.5% during the forecast period from 2026 to 2034. This robust valuation is anchored by the "2026 Digital Maturity Leap," where the widespread adoption of cloud-native, unified platforms has enabled pharmaceutical sponsors to reduce data management costs by nearly 67% compared to traditional paper-based methods. Furthermore, the 2026 update to the FDA’s "Computer Software Assurance (CSA)" guidance has streamlined the validation process for automated EDC workflows, allowing mid-sized biotech firms to deploy fully compliant, audit-ready databases in under a month—significantly accelerating the path to regulatory submission.

Pages : 231 | Published Date : 2026-05-09 | Report Code : IR1254

The Global Decentralized Clinical Trial Platform Market was valued at approximately USD 2.97 Billion in 2024 and reached USD 3.40 Billion in 2025. The market is projected to grow to USD 11.60 Billion by 2034, expanding at a CAGR of 14.6% during the forecast period from 2026 to 2034. This robust valuation is anchored by the "2026 Regulatory Maturity Milestone," as the full implementation of ICH E6(R3) guidelines has provided a global gold standard for remote data integrity. Furthermore, the 2026 commercialization of "Unified Data Fabric" architectures—which use AI-driven middleware to instantly harmonize disparate data from wearables and EHRs—is effectively resolving the interoperability bottlenecks that previously delayed 62% of decentralized programs, allowing sponsors to finally achieve the 30% reduction in study timelines promised by the DCT model.

Pages : 240 | Published Date : 2026-05-08 | Report Code : IR1253

The Global Biobetter Drug Market was valued at approximately USD 22.05 Billion in 2024 and reached USD 23.84 Billion in 2025. The market is projected to grow to USD 47.96 Billion by 2034, expanding at a CAGR of 8.1% during the forecast period from 2026 to 2034. This robust growth is driven by the "2026 Patient Compliance Pivot," where the industry is moving beyond mere therapeutic copies to value-added reformulations that significantly reduce administration times. Furthermore, the 2026 emergence of "Smart Delivery Integration"—which pairs biobetters with connected, absorption-enhancing subcutaneous devices—is effectively cutting hospital stay requirements, allowing for a broader transition to home-based care for chronic oncology and autoimmune patients.